Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
about
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasCurrent issues in malignant pleural mesothelioma evaluation and managementEvolving Therapies and FAK Inhibitors for the Treatment of CancerTargeting the epigenome in malignant pleural mesotheliomaNew histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expressionNew and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Novel therapies in phase II and III trials for malignant pleural mesothelioma.Medical treatment of mesothelioma: anything new?Belinostat: clinical applications in solid tumors and lymphoma.Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Molecular pathogenesis of malignant mesothelioma.Malignant pleural mesothelioma: from the bench to the bedside.Dendritic cell-based immunotherapy in mesothelioma.Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.Advances in systemic therapy for malignant mesothelioma: future perspectives.
P2860
Q26859274-54488229-A721-4A3B-B2A1-F6CE2D4E0F2FQ28393560-1B9D1C51-440A-4A41-8DEC-53A495435F1EQ28972291-6C2B9300-581E-4FA5-8DF6-3A433768C6B5Q33890546-E3247501-59CF-4E01-A828-E653195DDBEDQ34101029-1DEBE445-6952-4DEB-AE4C-9FDC32D8ED81Q34409219-98873F72-C183-447E-B898-2346CE405B4FQ34428778-CC69107D-8415-4DE6-A5BC-F42EE68D5A73Q34541123-C67DD4E5-1C7B-4D4C-9F9F-87CE29A40C0BQ35042668-43280E0B-8510-4FC6-AC9F-778F29DC23FCQ35129535-CF5D7F82-7F34-469C-851A-5776D6A5B9BEQ37866663-4D3ABFB8-90FA-4743-AFD3-2218524E4B5FQ37951994-527D9A6E-40D4-4E26-B11A-764BD1FE39BBQ37961738-E7612B14-641A-4044-81AD-95632BAE8A48Q38012566-E94EF13E-2D0A-486C-8CC5-C74C5610F540Q38019747-E1B31F31-8769-4357-9BE9-E5106C71D10CQ38059514-5ED8F008-1887-4069-85DD-26496A94592CQ38459546-4A5427CF-ACFE-4710-88EA-9D5353F9003FQ38674753-365EFFA7-2651-4FA5-845A-EF907338968CQ38748263-3AC28269-0AB9-4448-AB46-AF6385EEB6FCQ39432616-B1B5AE68-FC03-4758-B89C-4E3A0365F1CCQ47912434-90D059E4-276D-4630-8F09-584BAC29EA2A
P2860
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitors ...... rationale and clinical trials.
@en
Histone deacetylase inhibitors ...... rationale and clinical trials.
@nl
type
label
Histone deacetylase inhibitors ...... rationale and clinical trials.
@en
Histone deacetylase inhibitors ...... rationale and clinical trials.
@nl
prefLabel
Histone deacetylase inhibitors ...... rationale and clinical trials.
@en
Histone deacetylase inhibitors ...... rationale and clinical trials.
@nl
P2860
P1476
Histone deacetylase inhibitors ...... rationale and clinical trials.
@en
P2093
Lee M Krug
Paul K Paik
P2860
P304
P356
10.1097/JTO.0B013E3181C5E366
P577
2010-02-01T00:00:00Z